Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital Discloses New Stake in This Canadian Biotechnology Company

Page 1 of 2

Broadfin Capital, led by Kevin Kotler, has initiated a new position in QLT Inc. (USA) (NASDAQ:QLTI). In a new filing with the U.S. Securities and Exchange Commission, the fund has disclosed ownership of 4.45 million shares of QLT Inc. (USA) (NASDAQ:QLTI). The passive stake represents 8.7% of the company’s outstanding common stock. QLT Inc. (USA) (NASDAQ:QLTI) is a $219.40 million market cap biotechnology company engaged in the development and commercialization of ocular products.

Kevin Kotler

New York City-based Broadfin Capital is a global equity healthcare fund that was founded in 2005. The fund uses a fundamental, value-oriented investment strategy, and likes to invest in all the major subsectors of the healthcare industry. In its latest 13F with the SEC, Broadfin Capital revealed a public equity portfolio mainly consisting of healthcare stocks (over 85% of its value was in these stocks). The value of the funds’ public portfolio totaled $1.28 billion. As of March 31, Broadfin Capital’s top holdings, in terms of value, were Horizon Pharma PLC (NASDAQ:HZNP), Flamel Technologies S.A. (ADR) (NASDAQ:FLML), and Retrophin Inc (NASDAQ:RTRX), which we’ll also look at later.

Why do we pay attention to hedge fund sentiment? Most investors ignore hedge funds’ moves because as a group, their average net returns trailed the market since 2008 by a large margin. Unfortunately, most investors don’t realize that hedge funds are hedged and that they also charge an arm and a leg, so they are likely to underperform the market in a bull market. We ignore their short positions and found that by imitating hedge funds’ best stock picks independently, we don’t have to pay them a dime, while still getting the benefits of their stock-picking expertise. Our research has shown that hedge funds’ long stock picks generate strong risk-adjusted returns. For instance the 15 most popular small-cap stocks outperformed the S&P 500 Index by an average of 95 basis points per month in our back-tests spanning the 1999-2012 period. We have been tracking the performance of these stocks in real-time since the end of August 2012. These 15 stocks managed to return more than 145% over the last 34 months and outperformed the S&P 500 Index by 85 percentage points (see the details here).

Kevin Kotler
Kevin Kotler
Broadfin Capital

Canada-based QLT Inc. (USA) (NASDAQ:QLTI) is a maker of ocular products. The company, headquartered in Vancouver, British Columbia, develops a synthetic retinoid program for the treatment of certain inherited retinal diseases. In the second week of June, QLT Inc. (USA) (NASDAQ:QLTI) announced that it signed multiple agreements which would allow the company to return capital to its shareholders. QLT Inc. (USA) (NASDAQ:QLTI) inked a deal to acquire InSite Vision Inc. in an all-share transaction for $0.178 per share. This transaction, according to the company, will create a pure-play, late-stage ophthalmic pharmaceutical company to advance QLT’s existing Phase III-ready Retinoid Program. In addition, QLT agreed to a $45 million equity investment in Aralez Pharmaceuticals plc. Under the agreement, QLT will receive ordinary shares in Aralez representing about a 9% ownership stake. Further, QLT Inc. announced that it plans to issue redeemable convertible notes, returning an additional $25 million to its shareholders. The notes are expected to be issued by way of a reduction of the paid-up capital on the company’s common shares, and will provide QLT’s shareholders with an additional option of near-term liquidity or the potential for future capital investment in the company, according to a statement. Shares of QLT’s stock have declined 17.86% during the past year. Mark Lampert’s Biotechnology Value Fund is one of the largest shareholders of QLT Inc. (USA) (NASDAQ:QLTI), with ownership of 4.15 million shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!